Navigation Links
Study unveils SINE's potential of re-activating tumor fighting proteins within a cell
Date:11/15/2013

Arnhem, The Netherlands - New study suggests that selective blockade of CRM1-dependent nuclear export represents a completely novel, tumour metastasis-selective approach for the treatment of advanced metastatic prostate cancers.

According to the researchers, the human nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 (CRM1) is the sole exportin mediating transport of many multiple tumor suppressor proteins out of the nucleus. Their study aimed to verify the hypothesis that CRM1 inhibition could be beneficial for the treatment of prostate cancer metastases, which was achieved by testing the effects of the orally available, potent and selective, clinical stage SINE compound KPT 330.

"Although the class of compounds used in our studies SINEs or Selective Inhibitors of Nuclear Export have just recently entered early clinical testing, our results suggest that these agents could be active in patients with androgen-independent prostate cancer," commented study's lead author Dr. Claudio Festuccia, of the University of L'Aquila in Italy.

"Most of the current treatments for prostate cancer work by reducing the levels or blocking the receptors for a set of hormones called androgens. These SINE compounds act through an entirely new mechanism by re-activating a cells own tumor fighting proteins. These tumor fighting proteins, called tumor suppressor proteins, act as a guardian against the development of cancers by detecting damage to a cell's DNA and if DNA damage is found, activating the cell's own suicide program," he explained.

"Since all cancers have a great deal of DNA damage, re-activation of tumour suppressor proteins could cause the cancer to commit suicide. We observed just such an effect with these new SINE drug candidates."

According to the authors, the study also showed that these new SINE drug candidates prevented prostate cancer cells from causing damage to bones.

"The mechanisms of preventing the damage are now being worked out, but it appears that these new SINE drug candidates can suppress a type of bone cell called an osteoclast," said Festuccia.

Osteoclasts are activated by prostate cancer cells to destroy bone, and play an important role in prostate cancer-associated bone disease.


'/>"/>

Contact: Evgenia Starkova
e.starkova@uroweb.org
31-263-890-680
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
Breaking Medicine Technology: